Helena T. Hogberg

Agnes L. Karmaus, Anna L. Kreutz, Oluwakemi Oyetade, et al. Perspectives on variability of in vivo toxicology studies: considerations for next-generation toxicology. Frontiers in Toxicology. 2026;8. doi:10.3389/ftox.2026.1778353

Eike Cöllen, Kristina Bartmann, Jonathan Blum, et al. Mapping out strategies to further develop human-relevant, new approach methodology (NAM)-based developmental neurotoxicity (DNT) testing. ALTEX - Alternatives to animal experimentation. 2025. doi:10.14573/altex.2501091

Shu Yang, Kelly E. Carstens, Ibukunoluwa Ipaye, et al. High-throughput cytokine detection platform for evaluation of chemical induced microglial activation. SLAS Technology. 2025;35. doi:10.1016/j.slast.2025.100347

Susan J. Debad, Jason Aungst, Kelly Carstens, et al. State of the science on assessing developmental neurotoxicity using new approach methods. ALTEX - Alternatives to animal experimentation. 2025;42(1):121-144. doi:10.14573/altex.2410231

Ruth A. Roberts, Mamta Behl, Helena T. Hogberg, et al. Use of new approach methodologies (NAMs) in epilepsy research and seizure risk assessment. Drug Discovery Today. 2025;31(1):104569. doi:10.1016/j.drudis.2025.104569

Manuela Cassotta, Hugo Geerts, Lise Harbom, et al. The future of Parkinson’s disease research: A new paradigm of human-specific investigation is necessary… and possible. ALTEX. 2022;39(4):694-709. doi:10.14573/altex.2203161

David Pamies, Marcel Leist, Sandra Coecke, et al. Guidance document on Good Cell and Tissue Culture Practice 2.0 (GCCP 2.0). Alternatives to Animal Experimentation. 2022;39(1):30-70. doi:10.14573/altex.2111011

Thomas Hartung, Rob De Vries, Sebastian Hoffmann, et al. Toward Good In Vitro Reporting Standards. Alternatives to Animal Experimentation. 2019;36(1):3-17. doi:10.14573/altex.1812191